Compare Stocks: BNR, STTK, CBIO, and CTMX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$18.60 +3.3%	$10.80	$6.79 ▼ $41.72	$195.64M	1.38	60,237 shs	39,520 shs
CBIO Crescent Biopharma	$13.99 -1.8%	$17.09	$8.72 ▼ $27.41	$519.65M	1.24	531,328 shs	228,686 shs
CTMX CytomX Therapeutics	$2.70 -1.8%	$3.28	$2.66 ▼ $8.21	$588.33M	2.14	4.28 million shs	3.03 million shs
STTK Shattuck Labs	$6.07 -3.8%	$6.95	$1.70 ▼ $8.33	$609.20M	1.09	1.19 million shs	893,670 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	0.00%	+30.71%	+86.00%	+126.03%	+104.17%
CBIO Crescent Biopharma	0.00%	-17.17%	-21.23%	-24.31%	+7.78%
CTMX CytomX Therapeutics	0.00%	-2.17%	-21.05%	-20.24%	+12.03%
STTK Shattuck Labs	0.00%	+1.00%	-20.65%	-5.75%	+158.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$18.60 +3.3%	$10.80	$6.79 ▼ $41.72	$195.64M	1.38	60,237 shs	39,520 shs
CBIO Crescent Biopharma	$13.99 -1.8%	$17.09	$8.72 ▼ $27.41	$519.65M	1.24	531,328 shs	228,686 shs
CTMX CytomX Therapeutics	$2.70 -1.8%	$3.28	$2.66 ▼ $8.21	$588.33M	2.14	4.28 million shs	3.03 million shs
STTK Shattuck Labs	$6.07 -3.8%	$6.95	$1.70 ▼ $8.33	$609.20M	1.09	1.19 million shs	893,670 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	0.00%	+30.71%	+86.00%	+126.03%	+104.17%
CBIO Crescent Biopharma	0.00%	-17.17%	-21.23%	-24.31%	+7.78%
CTMX CytomX Therapeutics	0.00%	-2.17%	-21.05%	-20.24%	+12.03%
STTK Shattuck Labs	0.00%	+1.00%	-20.65%	-5.75%	+158.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
CBIO Crescent Biopharma	2.83	Moderate Buy	$29.60	111.58% Upside
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	340.74% Upside
STTK Shattuck Labs	3.00	Buy	$12.78	110.51% Upside

Current Analyst Ratings Breakdown

Latest BNR, STTK, CBIO, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
9/11/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/11/2026	STTK Shattuck Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/10/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$514.43M	0.38	N/A	N/A	$7.28 per share	2.55
CBIO Crescent Biopharma	$11.88M	43.73	N/A	N/A	$14.32 per share	0.98
CTMX CytomX Therapeutics	$76.20M	7.72	N/A	N/A	$0.58 per share	4.66
STTK Shattuck Labs	$1M	609.20	N/A	N/A	$1.30 per share	4.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.87	N/A	N/A	N/A	-13.60%	-12.98%	-8.59%	11/17/2026 (Estimated)
CBIO Crescent Biopharma	-$153.94M	-$6.72	N/A	N/A	N/A	N/A	-101.50%	-86.86%	11/5/2026 (Estimated)
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)

Latest BNR, STTK, CBIO, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	-$0.20	+$2.0883	-$0.25	$19.21 million	$19.84 million
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
7/30/2026	Q2 2026	CBIO Crescent Biopharma	-$0.7357	-$0.74	-$0.0043	-$0.74	$0.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.05	2.90
CBIO Crescent Biopharma	N/A	9.66	9.66
CTMX CytomX Therapeutics	N/A	9.36	9.36
STTK Shattuck Labs	N/A	27.59	27.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
CBIO Crescent Biopharma	75.19%
CTMX CytomX Therapeutics	67.77%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
CBIO Crescent Biopharma	24.84%
CTMX CytomX Therapeutics	3.80%
STTK Shattuck Labs	8.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	667	10.52 million	7.33 million	Not Optionable
CBIO Crescent Biopharma	44	37.14 million	27.92 million	No Data
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
STTK Shattuck Labs	40	100.36 million	91.54 million	Optionable

BNR, STTK, CBIO, and CTMX Headlines

Recent News About These Companies

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of "Buy" from Brokerages

September 25 at 8:13 AM | marketbeat.com

Shattuck Labs, Inc.(NasdaqGS:STTK) added to S&P Biotechnology Select Industry Index

September 21, 2026 | marketscreener.comM

Contrasting Shattuck Labs (NASDAQ:STTK) and AnaptysBio (NASDAQ:ANAB)

September 20, 2026 | americanbankingnews.com

Bank of New York Mellon Corp Buys New Stake in Shattuck Labs, Inc. $STTK

September 10, 2026 | marketbeat.com

Bank of America Corp DE Cuts Holdings in Shattuck Labs, Inc. $STTK

September 9, 2026 | marketbeat.com

Wellington Management Group LLP Makes New Investment in Shattuck Labs, Inc. $STTK

September 8, 2026 | marketbeat.com

3,750,000 Shares in Shattuck Labs, Inc. $STTK Purchased by Frazier Life Sciences Management L.P.

September 7, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Invests $1.58 Million in Shattuck Labs, Inc. $STTK

September 4, 2026 | marketbeat.com

BlackRock Inc. Invests $27.32 Million in Shattuck Labs, Inc. $STTK

September 3, 2026 | marketbeat.com

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

September 2, 2026 | globenewswire.com

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

September 1, 2026 | seekingalpha.com

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of "Buy" from Brokerages

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.99 Million in Shattuck Labs, Inc. $STTK

August 30, 2026 | marketbeat.com

356,528 Shares in Shattuck Labs, Inc. $STTK Bought by Deutsche Bank AG

August 28, 2026 | marketbeat.com

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

August 20, 2026 | zacks.com

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

August 13, 2026 | zacks.com

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

August 12, 2026 | tipranks.com

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026 | markets.businessinsider.com

Shattuck Labs Releases Q2 2026 10-Q Filing Highlighting Key Risk Factors and Share Count

August 11, 2026 | kalkinemedia.comK

Shattuck Labs Reports Positive Phase 1 Data for SL-325 and Advances DR3 Pipeline with Phase 2b Crohn’s Study Planned for 2026

August 11, 2026 | quiverquant.comQ

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

July 24, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, STTK, CBIO, and CTMX Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$18.60 +0.60 (+3.33%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$18.84 +0.24 (+1.32%)

As of 09/25/2026 07:30 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Crescent Biopharma NASDAQ:CBIO

$13.99 -0.25 (-1.76%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$14.25 +0.26 (+1.85%)

As of 09/25/2026 07:30 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

CytomX Therapeutics NASDAQ:CTMX

$2.70 -0.05 (-1.82%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$2.70 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Shattuck Labs NASDAQ:STTK

$6.07 -0.24 (-3.80%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$6.04 -0.04 (-0.58%)

As of 09/25/2026 07:30 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, STTK, CBIO, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, STTK, CBIO, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, STTK, CBIO, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, STTK, CBIO, and CTMX Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Crescent Biopharma NASDAQ:CBIO

CytomX Therapeutics NASDAQ:CTMX

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, STTK, CBIO, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, STTK, CBIO, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, STTK, CBIO, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, STTK, CBIO, and CTMX Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Crescent Biopharma NASDAQ:CBIO

CytomX Therapeutics NASDAQ:CTMX

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools